



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Application of:

Francois HIRSCH et al.

Serial No.: 09/926,493

Group Art Unit:1645

Filed: January 24, 2002

For: NUCLEIC ACID-ANTIBODY CONJUGATE FOR DELIVERY A FOREIGN NUCLEIC  
ACID IN CELLS

#8 / I.D.S.

INFORMATION DISCLOSURE STATEMENT

RECEIVED

Commissioner of Patents  
Washington, DC 20231

JUN 28 2002

Sir:

TECH CENTER 1600/2900

As a means of complying with the duty of disclosure under 37 CFR §1.56, and in accordance with 37 CFR §§1.97 and 1.98, Applicant(s), through the undersigned attorney, submits this Information Disclosure Statement. The patents, publications or other information submitted herewith are listed on the attached Form PTO-1449 and copies are attached. The Examiner is requested to make these references of record in the file of this application.

The listed publications are cited as follows:

International Search Report	All of Item A with exception of AK
French Preliminary Search Report	All of Item A with exception of AE, AI, AJ, AK, AP and AQ
Specification	Items AB, AC, AD, AK and all of Items B, C and D


A copy of the search reports is enclosed. Note that FR 2 786 104 is equivalent to FR 98/14858 in the specification.

In accordance with 37 CFR §1.97(b)(3), this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits of the above-identified application.

Respectfully submitted,

JACOBSON HOLMAN PLLC

400 Seventh Street, N.W.  
Washington, DC 20004  
(202) 638-6666  
Atty. Dkt. No.: P67289US0  
HBJ/dlj

By:   
Harvey B. Jacobson, Jr.  
Registration No. 20,851



JACOBSON HOLMAN PLLC  
400 SEVENTH STREET, N.W.  
WASHINGTON, D.C. 20004-2201

#8/L.D.S.  
RECEIVED

JUN 28 2002

TECH CENTER 1600/2900

ATTY. DOCKET NO.: P67289US0 GROUP ART UNIT: 1645  
SERIAL NO.: 09/926,493 FILING DATE: January 24, 2002  
APPLICANT(S): Francois HIRSCH et al.

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE (If Appropriate)
	AA 5,166,320	11/24/92	Wu et al.	530	395	
	AB 5,428,132	6/27/95	Hirsch et al.	530	387.1	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES) (NO)
	AC 88/08854	11/17/88	WIPO			:
	AD 94/04696	3/3/94	WIPO			:
	AE 94/13325	6/23/94	WIPO			:
	AF 95/21195	8/10/95	WIPO			:
	AG 96/13599	5/9/96	WIPO			:
	AH 98/02564	1/22/98	WIPO			:
	AI 98/47538	10/29/98	WIPO			partial
	AJ 98/56425	12/17/98	WIPO			:
	AK 2 786 104	5/26/00	France			partial

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AL XP-000877306; Poncet et al.; Antifection: an antibody-mediated method to introduce genes into lymphoid cells in vitro and in vivo; Gene Therapy; (1996) 3 731-738

AM XP-002133110; Fominaya et al.; Target Cell-specific DNA Transfer Mediated by a Chimeric Multidomain Protein; The Journal of Biological Chemistry; Vol. 271, No. 15, (1996) 10560-10568

AN XP-002133111; No. 237; Chakrabarti et al.; Transfer of DNA into Lymphoma Cells by DNA-Bound to T101-Biotinylated-Avidin-Polysine Antibody Complex

AO XP-002133112; Guy et al.; Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene therapy

AP XP-002155195; Traut et al.; Location and domain structure of Escherichia coli ribosomal protein L7/L12

AQ XP-002155196; Hockett et al.; Evidence for targeted gene transfer by receptor-mediated Endocytosis stable expression following insulin-directed entry of Neo into HepG2 cells

EXAMINER

DATE CONSIDERED



JACOBSON HOLMAN PLLC  
400 SEVENTH STREET, N.W.  
WASHINGTON, D.C. 20004-2201

Sheet 2 of 4  
**RECEIVED**

JUN 28 2002

LIST OF REFERENCES AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.: P67289US0

GROUP ART UNIT: 1645

SERIAL NO.: 09/926,493

FILING DATE: January 24, 2002

APPLICANT(S): Francois HIRSCH et al.

TECH CENTER 1600/2900

\*\*\*\*\*


**OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

- BA #1603; Angevin et al.; Characterization of a renal cell carcinoma (RCC) xenograft model in immunodeficient SCID mice; Proc. Am. Asso. Cancer Res. 38 (1997) 238
- BB Angevin et al.; Analysis of T-cell immune response in renal cell carcinoma: Polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity; Int. J. Cancer, 72 (1997), 431-440
- BC Brandtzaeg; Conjugates of Immunoglobulin G with Different Fluorochromes. I. Characterization by Anionic-exchange Chromatography; Scand. J. Immunol. 2 (1973) 273-290
- BD Chittenden et al.; Induction of apoptosis by the Bcl-2 homologue Bak; Nature 374 (1995) 733-736
- BE Cournover et al.; Gene transfer of adenosine deaminase into primitive human hematopoietic progenitor cells; Human Gene Therapy, 2 (1991) 203-213
- BF Dubés et al.; Rapid ephemeral cell sensitization as the mechanism of histone-induced and protamine-induced enhancement of transfection by Poliovirus RNA; Protoplasma 96 (1978) 209-223
- BG Fominaya et al.; Target cell-specific DNA transfer mediated by a chimeric multidomain protein; J. Biol. Chem., 271 (1996) 10560-10568
- BH Golumbek et al.; Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4; Science, 254 (1991) 713-716
- BI Glukhova et al.; Overrepresentation of 7q31 and 17q in Renal Cell Carcinomas; Genes Chrom. Cancer, 22 (1998) 171-178
- BJ Hirsch et al.; Antifection: A New Method for Targeted Gene Transfection; Transplantation Proceedings, Vol. 25, No. 1, (1993) 138-139
- BK Karasuyama et al.; Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors; Eur. J. Immunol. 18; (1988) 97-104
- BL Kiefer et al.; Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak; Nature 374; (1995), 736-739
- BM Luthman et al.; High efficiency polyoma DNA transfection of chloroquine treated cells; Nucleic Acids Res.; 11 (1983) 1295-1308

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



JACOBSON HOLMAN PLLC  
400 SEVENTH STREET, N.W.  
WASHINGTON, D.C. 20004-2201

Sheet 3 of 4

RECEIVED

JUN 28 2002

TECH CENTER 1600/2900

ATTY. DOCKET NO.: P67289US0 GROUP ART UNIT: 1645  
SERIAL NO.: 09/926,493 FILING DATE: January 24, 2002  
APPLICANT(S): Francois HIRSCH et al.

\*\*\*\*\*

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

- CA Maxfield et al.; Collection of Insulin, EGF and  $\alpha_2$ -Macroglobulin in the Same Patches on the Surface of Cultured Fibroblasts and Common Internalization; Cell 14 (1978) 805-810
- CB Michael et al.; Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway; Gene Therapy, 1 (1994) 223-232
- CC Neda et al.; Chemical modification of an Ecotropic Murine Leukemia Virus Results in Redirection of Its Target Cell Specificity; J. Biol. Chem.; 226 (1991) 14143-14146
- CD Old; Tumor Necrosis Factor (TNF); Science, Vol. 230, (1985) 630-632
- CE Oltvai et al.; Bcl-2 Heterodimerizes In Vivo with a Conserved Homolog, Bax, That Accelerates Programed Cell Death; Cell 74; (1993) 609-619
- CF Oosterwuk et al.; Monoclonal Antibody G250 Recognizes a Determinant Present in Renal-Cell Carcinoma and Absent from Normal Kidney; Int. J. Cancer.; 38; (1986), 489-494
- CG Poncet et al.; Antifection: an antibody-mediated method to introduce genes into lymphoid cells in vitro and in vivo; Gene Therapy; 3 (1996), 731-738
- CH Ragot et al.; Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice; Nature 361 (1993); 647-650
- CI Rosenberg et al.; Gene Transfer into Humans - Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction; N. Eng. J. Med.; 323 (1990); 570-578
- CJ Roux et al.; A versatile and potentially general approach to the targeting of specific cell types by retroviruses: Application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses; Proc. Natl. Acad. Sci. USA 86 (1989), 9079-9083
- CK Susin et al.; Molecular characterization of mitochondrial apoptosis-inducing factor; Nature; 397 (1999); 441-446
- CL Takahashi et al.; Human Fas ligand: Gene structure chromosomal location and species specificity; Int. Immun.; 6 (1994); 1567-1574

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



JACOBSON HOLMAN PLLC  
400 SEVENTH STREET, N.W.  
WASHINGTON, D.C. 20004-2201

Sheet 4 of 4

RECEIVED

JUN 28 2002

PATENT &amp; TRADEMARK OFFICE

TECH CENTER 1600/2900

ATTY. DOCKET NO.: P67289US0 GROUP ART UNIT: 1645  
SERIAL NO.: 09/926,493 FILING DATE: January 24, 2002  
APPLICANT(S): Francois HIRSCH et al.

\*\*\*\*\*

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DA Wang et al.; BID: a novel BH3 domain-only death agonist; Genes & Development; 10 (1996), 2859-2869

DB Wienhues et al.; Laboratory Methods, A Novel method for Transfection and Expression of Reconstituted DNA-Protein Complexes in Eukaryotic Cells; DNA 6(1), (1987), 81-89

DC Wu et al., Receptor-mediated Gene Delivery in Vivo, J. Biol. Chem., 266 (1991), 14338-14342

DD Zenke et al.; Receptor-mediated endocytosis of transferrin-polycation conjugates: An efficient way to introduce DNA into hematopoietic cells; Proc. Natl. Acad. Sci. USA; 87 (1990) 3655-3659

DE \_\_\_\_\_

DF \_\_\_\_\_

DG \_\_\_\_\_

DH \_\_\_\_\_

DI \_\_\_\_\_

DJ \_\_\_\_\_

DK \_\_\_\_\_

DL \_\_\_\_\_

DM \_\_\_\_\_

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).